Study identifier:D1692C00014
ClinicalTrials.gov identifier:NCT02200666
EudraCT identifier:N/A
CTIS identifier:N/A
Forxiga Tablets Specific Clinical Experience Investigation for long-term use
Type 2 Diabetes Mellitus
N/A
No
-
All
7793
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2020 by AstraZeneca
AstraZeneca
-
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga) -Development of ADRs specified as Key Investigation Items and the risk factors -Contributing factors possibly having an impact on the safety and efficacy -Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use
Location
Location
Hokkaido, Japan, D1692C00014
Location
Hokkaido, Japan, D1692C00014
Location
Aomori, Japan, D1692C00014
Location
Aomori, Japan, D1692C00014
Location
Iwate, Japan, D1692C00014
Location
Iwate, Japan, D1692C00014
Location
Miyagi, Japan, D1692C00014
Location
Miyagi, Japan, D1692C00014
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.